NCT06508099View on ClinicalTrials.gov

Vitamin A and D Supplementation in Allogeneic HCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBiphenotypic Acute LeukemiaLymphoblastic LymphomaChronic Myeloid LeukemiaMyelodysplastic SyndromesMyeloprolipherative NeoplsmNon-hodgkin Lymphoma
Interventions
DRUG

Vitamin A

300 000 IU single dose orally

DRUG

Vitamin D3

100 000 IU single dose orally

Trial Locations (1)

197022

RECRUITING

RM Gorbacheva Research Institute, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER